Preventing Venous Thromboembolism: Apixaban More Effective With Solid Tumors

A preplanned post-hoc analysis of the AVERT trial, a randomized, placebo-controlled, double-blind clinical trial of apixaban for the prevention of venous thromboembolism (VTE), reveals that among ambulatory patients with cancer initiating chemotherapy, characteristics of both the patient and the cancer in question impact the efficacy of apixaban for VTE prophylaxis. "Patients with active cancer have an increased risk of venous thromboembolism (VTE) complications which is associated with morbidit...
Continue reading

Preventing Venous Thromboembolism in Patients With Cancer: An Interview With Philip Wells, MD, FRCPC, MSc

​Venous thromboembolism is the third most common vascular condition after heart attack and stroke, affecting between 300,000 and 600,000 individuals in the United States each year. Patients with active cancer are at increased risk, with a 9.6% chance of developing symptomatic thrombosis during the first six months of chemotherapy. In this interview with i3 Health, hematologist Philip Wells, MD, FRCPC, MSc, Chair and Chief of the Department of Medicine at the University of Ottawa and The Ottawa H...
Continue reading

Apixaban Prevents Venous Thromboembolism in Patients With Cancer

​A team of Canadian researchers has found that apixaban reduces the occurrence of venous thromboembolism in cancer patients who are starting chemotherapy and are at intermediate to high risk for this condition. A blood clot that forms in the veins, venous thromboembolism is the third most common vascular condition after heart attack and stroke, affecting between 300,000 and 600,000 individuals in the United States each year. Patients with active cancer are at increased risk, with a 9.6% chance o...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.